Nicholas George Strong
Plus aucun poste en cours
Profil
Nicholas George Strong worked as a Finance Director at EiRx Therapeutics Plc, NovaBiotics Ltd., and Cahill May Roberts Ltd.
He also worked as a Senior Manager-Finance at Shell International Ltd.
In addition, he served as a Board Member at Helix Health Group Ltd.
in 2013.
Strong obtained an undergraduate degree from the University of Cambridge.
Anciens postes connus de Nicholas George Strong
| Sociétés | Poste | Fin |
|---|---|---|
Shell International Ltd.
 Shell International Ltd. Miscellaneous Commercial ServicesCommercial Services Shell International Ltd. provides business support services. It engages in upstream and downstream oil and gas businesses in the United Kingdom and internationally. The company is headquartered in London, the United Kingdom. | Directeur Financier/CFO | - |
Cahill May Roberts Ltd.
 Cahill May Roberts Ltd. Medical DistributorsDistribution Services Part of UniPhar Group Ltd., Cahill May Roberts Ltd. is a pharmaceutical product distributor. The company is based in Chapelizod, Ireland. Cahill May Roberts was acquired by UniPhar Group Ltd. from McKesson Europe AG on April 30, 2013 for $63.43 million. | Directeur Financier/CFO | - |
NovaBiotics Ltd.
 NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | Directeur Financier/CFO | - |
Helix Health Group Ltd.
 Helix Health Group Ltd. Pharmaceuticals: MajorHealth Technology Helix Health Group Ltd. provides practice management and pharmacy software services. The company was founded by Howard J. Beggs on November 10, 2006 and is headquartered in Dublin, Ireland. | Directeur Financier/CFO | 03/06/2013 |
EiRx Therapeutics Plc
 EiRx Therapeutics Plc Miscellaneous Commercial ServicesCommercial Services The Group's principal activity is discovering and developing novel therapeutics for the treatment of cancer. It focuses on the study of cancer cell survival and growth, with a research base encompassing apoptosis biology, cancer biomarkers and the metabolic basis of drug resistance in tumours. The Group creates intellectual property that seeks to exploit through in-house product development and licensing. | Directeur Financier/CFO | - |
Formation de Nicholas George Strong
| University of Cambridge | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 5 |
|---|---|
EiRx Therapeutics Plc
EiRx Therapeutics Plc Miscellaneous Commercial ServicesCommercial Services The Group's principal activity is discovering and developing novel therapeutics for the treatment of cancer. It focuses on the study of cancer cell survival and growth, with a research base encompassing apoptosis biology, cancer biomarkers and the metabolic basis of drug resistance in tumours. The Group creates intellectual property that seeks to exploit through in-house product development and licensing. | Commercial Services |
NovaBiotics Ltd.
NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | Health Technology |
Helix Health Group Ltd.
Helix Health Group Ltd. Pharmaceuticals: MajorHealth Technology Helix Health Group Ltd. provides practice management and pharmacy software services. The company was founded by Howard J. Beggs on November 10, 2006 and is headquartered in Dublin, Ireland. | Health Technology |
Cahill May Roberts Ltd.
Cahill May Roberts Ltd. Medical DistributorsDistribution Services Part of UniPhar Group Ltd., Cahill May Roberts Ltd. is a pharmaceutical product distributor. The company is based in Chapelizod, Ireland. Cahill May Roberts was acquired by UniPhar Group Ltd. from McKesson Europe AG on April 30, 2013 for $63.43 million. | Distribution Services |
Shell International Ltd.
Shell International Ltd. Miscellaneous Commercial ServicesCommercial Services Shell International Ltd. provides business support services. It engages in upstream and downstream oil and gas businesses in the United Kingdom and internationally. The company is headquartered in London, the United Kingdom. | Commercial Services |
